Randomised Phase III Trial With Capecitabine/Erlotinib Followed of Gemcitabine Versus Gemcitabine/Erlotnib Followed of Capecitabine in Patients With Advanced Pancreatic Cancer.

Trial Profile

Randomised Phase III Trial With Capecitabine/Erlotinib Followed of Gemcitabine Versus Gemcitabine/Erlotnib Followed of Capecitabine in Patients With Advanced Pancreatic Cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jul 2015

At a glance

  • Drugs Capecitabine; Erlotinib; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Jul 2012 The non-inferiority of treatment regimens on the primary endpoint 'Time-to-treatment-failure' has been met according to results published in Gut.
    • 07 Jul 2012 Final results published in the Gut.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top